Pharmaceuticals, Biotechnology and Life Sciences
City of Hope was awarded $5.3 million from CIRM to develop a treatment for metastatic ovarian cancer using Calidi’s licensed…
CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $159 million and $500 million for the fourth quarter and full…
– Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand…
SAN FRANCISCO–(BUSINESS WIRE)–Ossium Health, an innovative bioengineering company that develops bone marrow-derived cell therapies, announced today that it has been…
Presence of SENS-401 in the perilymph is confirmed in 100% of the patients sampled following cochlear implantation at levels compatible…
The late-breaking session at the American Academy of Dermatology (AAD) Annual Meeting offers a first look at data from 17…
Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing…
Randomized Phase 2 study met the primary endpoint in patents with hidradenitis suppurativa (HS), reinforcing efficacy and safety profile of…
Nemolizumab is a first-in-class investigational monoclonal antibody designed to provide relief from itch by targeting IL-31 One-year data from an…
Company has promoted Leesa Gentry to Chief Clinical Officer and Ronald B. Kocak to Principal Accounting Officer LOS ALTOS, Calif.–(BUSINESS…